Vanguard Global Advisers’s Vaxcyte PCVX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.25M Buy
57,157
+7,370
+15% +$430K ﹤0.01% 969
2026
Q2
$2.89M Sell
49,787
-1,863
-4% -$101K ﹤0.01% 1027
2026
Q1
$3M Buy
+51,650
New +$2.8M ﹤0.01% 969

Other funds holding PCVX

Vanguard Global Advisers's PCVX Position: Q3 2026 in Review

Vanguard Global Advisers increased its Vaxcyte (PCVX) stake by 15% in Q3 2026, buying an estimated $430K and bringing the position to 57,157 shares worth $3.25M. The position accounts for ﹤0.01% of the portfolio, ranked #969.

Vanguard Global Advisers first reported a position in PCVX in Q1 2026 and has held it in 3 quarters since. 297 funds tracked by Wall St. Rank hold PCVX as of Q3 2026.

  • Vanguard Global Advisers held 57,157 shares of Vaxcyte worth $3.25M as of Q3 2026.
  • Vanguard Global Advisers bought 7,370 Vaxcyte shares in Q3 2026, an estimated $430K.
  • Vaxcyte made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #969 holding.
  • Vanguard Global Advisers first reported a position in Vaxcyte in Q1 2026 and has held it in 3 quarters since.
  • 297 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.